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Abstract
Background: Anti-tumour necrosis factor [TNF] therapy in combination with thiopurine is the most 
effective strategy for Crohn’s disease, but raises safety concerns.
Methods: In a retrospective multicentre study, we investigated long-term outcome of patients starting 
anti-TNF monotherapy for Crohn’s disease and investigated whether introducing an immunomodulator 
in patients losing response to anti-TNF monotherapy is effective for resetting immunogenicity.
Results: A total of 350 adult patients with Crohn’s disease received either infliximab [n  =  178, 
51%] or adalimumab [n = 172, 49%] monotherapy. Mean duration of follow-up was 42 months. 
An immunomodulator was initiated in 53 patients [15%]. At last follow-up, 73.1% [n = 38] were in 
clinical remission [one patient with missing data]. Multivariate analysis identified anti-TNF type 
[higher need for starting immunomodulator for infliximab than for adalimumab; p = 0.0058] and 
first- vs second-/third-/fourth-line anti-TNF therapy [p = 0.014] as predictors of immunomodulator 
initiation. Among the 18 patients with available data, introduction of an immunomodulator was 
able to restore infliximab trough level within the therapeutic range and to induce clinical remission 
in 10 patients [55%]. Cumulative probability of remaining on anti-TNF therapy was 57.9% at 5 years 
among the 297 patients not starting an immunomodulator during follow-up.
Conclusion: An immunomodulator was initiated in 15% of patients with Crohn’s disease starting anti-
TNF monotherapy. Independent predictors of immunomodulator initiation were infliximab use and 
second-/third-/fourth-line anti-TNF therapy. Resetting immunogenicity with an immunomodulator 
was effective in half of patients in a sub-study. Persistence of anti-TNF treatment at 5 years was 
observed in half of the 297 patients not starting an immumodulator in a real-life setting.
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1. Introduction
Crohn’s disease [CD] is a chronic disabling and progressive condi-
tion.1 Anti-tumour necrosis factor [TNF] therapy is increasingly used 
to treat inflammatory bowel disease [IBD] refractory to standard 
medications.2,3 The SONIC trial demonstrated that infliximab in com-
bination therapy with azathioprine is the most effective strategy for 
CD.4 A SONIC-like trial is not available for other biologicals known 








to be effective in CD, namely adalimumab, certolizumab pegol, 
vedolizumab, and natalizumab. A recent French nationwide survey 
among private gastroenterologists found that the use of combination 
therapy is very low, representing only 4.5% of IBD patients in a real-
life setting.5 This may be partly explained by safety concerns such as 
lymphoma risk associated with the use of combination therapy.6,7 By 
contrast, there is no increased risk of malignancy among IBD patients 
treated with anti-TNF monotherapy except for skin cancers.6,7
Anti-TNF monotherapy may be associated with a better safety 
profile than combination therapy, especially in some specific patient 
populations such as young males and elderly people.6,7
Accumulating evidence indicates that combination therapy reduces 
immunogenicity of anti-TNF therapy and improves trough levels in 
IBD patients.6,7 Interestingly, a recent pilot study suggested that the 
addition of an immunomodulator to anti-TNF therapy might be effec-
tive in patients who have lost response to anti-TNF agents owing to 
formation of antidrug antibodies.8 Levels of antibodies to infliximab 
[ATI] gradually decreased while trough levels of infliximab [TRI] 
increased; clinical response was restored in all five included patients.8
We therefore evaluated in a large multicentre retrospective study, 
enrolling all consecutive adult patients who started anti-TNF mono-
therapy for CD in four referral centres, the short- and long-term 
outcomes of these patients. We also investigated whether starting 
an immunomodulator among patients losing response to anti-TNF 
monotherapy could be used for resetting immunogenicity and 
improving pharmacokinetics without representing a loss of opportu-
nity for these patients.
2. Methods
2.1. Study population
All consecutive adult patients treated between January 1, 2000 and 
March 16, 2013 in four referral centres (Nancy, Nice, and Saint-
Etienne [France] and Liège [Belgium]) with anti-TNF monotherapy 
[infliximab or adalimumab] as a first-, second-, third- or fourth-line 
anti-TNF-therapy were included in this retrospective study. Patients 
receiving episodic anti-TNF treatment were excluded. Short-term 
efficacy of anti-TNF monotherapy was evaluated at Weeks 4–12 
and was classified as no response, partial response, or complete 
response. Response was judged by the physician, as no clinical score 
is routinely used in any of the participating centres and as it was 
a retrospective study. Long-term efficacy was evaluated by record-
ing anti-TNF persistence as well as clinical benefit at last known 
follow-up. The need for initiating an immunomodulator during 
follow-up was evaluated. All CD-related surgeries and hospitalisa-
tions were collected. All adverse events occurring during follow-up 
were recorded.
In the subgroup of patients followed at Saint-Etienne University 
Hospital, TRI and ATI were measured according to routine practice 
in all patients losing clinical response to infliximab therapy [ELISA 
technique from Theradiag, Marne La Vallée, France]. Faecal calpro-
tectin levels and Crohn’s Disease Activity Index [CDAI] scores were 
also collected in this centre according to routine practice. If patients 
had undetectable TRI with high ATI [> 200 ng/ml]9, azathioprine 
was then introduced [2.5mg/kg/d] without modification of inflixi-
mab dose.
2.2. Statistical analysis
Qualitative variables were given as frequency and percentage. 
Quantitative variables were calculated as medians with interquartile 
range [IQR].
The cumulative incidences of optimising anti-TNF therapy, 
remaining on anti-TNF therapy and on combination therapy, start-
ing an immunomodulator, and experiencing an adverse event related 
to the immunomodulator were calculated using the Kaplan-Meier 
estimator. When possible, the median survival time and its 95% con-
fidence interval [95% CI] were computed.
Potential predictive factors of immunomodulator initiation were 
first tested by bivariate analyses using the Cox proportional hazards 
model. Parameters with a p-value less than 0.2 in bivariate analysis 
were introduced in a multivariate Cox proportional hazards model 
with backward selection. Results were expressed with hazard ratio 
and its 95% confidence interval [95% CI]. To investigate predic-
tors of clinical remission after immunomodulatory introduction, 
uncontrolled disease and partial response were pooled and we used 
bivariate Cox proportional-hazards model. Univariate analysis was 
performed to identify independent predictors of clinical remission 
Table 1. Demographic and baseline characteristics at anti- tumour 
necrosis factor [TNF] monotherapy initiation.
Parameter N = 350
Age 35.2 [23.7;43.9]
Gender [male] 44.3% [155]
Active smoker 54.9% [162]
Duration of disease [years] 4.4 [1.5;12.1]
Number line of biological therapy
  •1st line 68.6% [240]
  •2nd line 29.1% [102]
  •3rd line 2.0% [7]
  •4th line 0.3% [1]
Age at diagnosis [years]a
  •< 16 13.9% [47]
  •17–40 68.7% [233]
  •> 40 17.4% [59]
Localisation of diseasea
  •Ileum: L1 36.6% [123]
  •Colon: L2 20.3% [70]
  •Ileocolon: L3 43.0% [148]
Behavioura
  •Pure inflammatory: B1 57.7% [195]
  •Stricturing: B2 25.1% [85]
  •Penetrating: B3 17.2% [58]
Perianal disease 39.0% [137]
Previous intestinal resection 33.1% [115]
Concomitant medications
  •Oral 5-ASA 9.8% [34]
  •Budesonide 8.7% [30]
  •Systemic [oral or intravenous] steroids 23.3% [81]
  •Ciclosporin 1.1% [4]
Indication of anti-TNF monotherapy initiation
  •Complicated behaviour 34.6% [121]
  •Flare 13.1% [46]
  •Fistula 19.4% [68]
  •Stenosis 15.1% [53]
  •Prophylaxis 8.3% [29]
  •Manifestation extra-digestive 7.7% [27]
  •Steroid-dependent disease 16.9% [59]
  •Steroid-refractory disease 14.0% [49]
  •Immunosuppressicve therapy failure 26.3% [92]
  •Failure of a first anti-TNF therapy 12.6% [44]
Results are expressed as median [interquartile range] for quantitative pa-
rameters and as percentage [frequency] for qualitative parameters.
5-ASA, 5-aminosalicylic acid.
aAccording to the Montreal classification
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and pharmacokinetics normalisation after introduction of azathio-
prine in the subgroup of patients with available information.
Data were analysed with SAS software version 9.2 [SAS Inc., 
Cary, NC 27513]. A p-value less than 0.05 was considered significant.
3. Results
3.1. Baseline characteristics of the 350 patients
The median duration of follow-up since anti-TNF monotherapy 
initiation  for  the  overall  population was  35 months  [IQR:  18.3–
53.3] [Table  1]. Median age at anti-TNF monotherapy initiation 
was 32.2 years [23.7–43.9] and 155 patients were males [44.3%]. 
Median disease duration at time of anti-TNF monotherapy initia-
tion was 4.4  years [1.5–12.1]; 240 patients [68.6%] started anti-
TNF monotherapy as first-line anti-TNF therapy; the remaining 110 
patients started first-line anti-TNF therapy in association with an 
immunomodulator and received anti-TNF monotherapy as second-, 
third-, or fourth-line anti-TNF therapy. Anti-TNF monotherapy 
was infliximab [n  =  178, 51%] or adalimumab [n  =  172, 49%]. 
According to the Montreal classification, 126 [36.7%] patients had 
ileal disase [L1], 70 [20.3%] colonic disease [L2], and 148 [43.0%] 
ileocolonic disease. A total of 195 [57.7%] patients had uncompli-
cated disease, 85 [25.1%] patients had stricturing behaviour, and 
58 [17.1%] had penetrating behaviour. Of the 350 patients, 137 
[39%] had perianal disease. One-third of patients had previous 
intestinal resection. About 10% of patients were on an oral 5-amon-
isalicylate [5-ASA], 30 [8.7%] on budesonide, and 81 [23.3%] on 
systemic [oral or intravenous] steroids. The main indications of anti-
TNF monotherapy were a complicated behaviour for 121 patients 
[34.6%], steroid-dependent or -refractory disease for 108 patients 
[31%], immunosuppressive therapy failure for 92 [26.3%], and fail-
ure of a first anti-TNF therapy for 44 [12.6%] patients [Table 1].
3.2. Short-term clinical efficacy of anti-TNF 
monotherapy
Clinical efficacy as judged by the physician after anti-TNF induction 
therapy was observed in 94% of patients [complete response 65.7% 
and partial response 28.4%], and non-primary response in 6% of 
patients.
3.3. Long-term outcome of anti-TNF monotherapy
Anti-TNF therapy optimisation [shortening interval and/or increas-
ing the dose] was performed in 163 [47.8%; missing data for 9 out 
of 350 patients] of 350 patients during follow-up. The cumulative 
probability of  optimising  anti-TNF  therapy was 26.9%  [95% CI: 
22.4%; 32.1%] and 58.8% [51.8%; 65.9%] at 1 and 5 years, respec-
tively [Supplementary Figure 1, available as Supplementary data at 
ECCO-JCC online]. Median time to optimisation was 47 months 
[28;56]. Of the 163 patients, 80% of patients shortened the inter-
val between infliximab infusions or adalimumab injections, whereas 
20% increased the dose of anti-TNF treatment.
After a median follow-up of 33 months [IQR: 17–52], 297 [85%] 
out of 350 patients did not require the introduction of an immu-
nomodulator; 92 out of 297 patients stopped anti-TNF therapy 
during follow-up. Of these 92 patients, 42 [46.7%] were switched 
to another anti-TNF agent, 10 [11.1%] stopped when they under-
went intestinal resection, 8 [8.9%] stopped while being in clinical 
benefit, and the 32 remaining patients for other reasons. The cumu-
lative probability of remaining on anti-TNF therapy from time of 
anti-TNF monotherapy initiation for the 297 patients was 90.6% 
[86.0%;93.2%] and 57.9% [49.9%;64.9%] at 1 and 5  years, 
respectively [Figure 1]. At last follow-up, 75.4% [n = 215] of the 
297 patients who did not start an immunomodulator were in clini-
cal remission as judged by the physician, 16.8% [n = 48] had partial 































Patients at risk, n
297 231 153 106 62 37 18
12 24
Time since anti-TNF monotherapy initiation (months)
36 48 60 72
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Figure 1. Cumulative probability of remaining on anti-tumour necrosis factor [TNF] therapy from time of anti-TNF monotherapy initiation in the 297 patients not 
needing an immunomodulator during follow-up.
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3.4. Long-term outcome of the 53 patients starting 
an immunomodulator
After a median follow-up of 12.8  months [range, 4.5–30.1], an 
immunomodulator was initiated in 53 out of 350 patients [15%]: 
33 [62%] with azathioprine and 20 [38%] with methotrexate. 
The cumulative probability of starting an immunomodulator was 
7.1% [4.8%;10.5%] and 25.9% [19.5%;33.9%] at 1 and 5 years, 
respectively [Figure 2A]. At last follow-up, 28.9% of the 53 patients 
were still on combination therapy, 46.1% were on anti-TNF mono-
therapy [and thus had stopped the immunomodulator], 9.6% were 
on immunomodulator alone [and thus had stopped the anti-TNF 
agent], and 13.4% had stopped both anti-TNF therapy and immu-
nomodulator. The probability of remaining on combination ther-
apy [ie patients who stopped neither the anti-TNF agent nor the 
immunomodulator] from time of immunomodulator initiation for 
the 53 patients was 61.8% [46.3%; 73.9%] and 31.8% [17.1%; 
47.6%] at 6 and 24 months, respectively [Figure 2B]. This prob-
ability was 50.6% [30.3%; 74.8%] at 12 months for patients on 
methotrexate and 48.6% [31.5%; 68.9%] for patients on azathio-
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Patients at risk, n
53 27 16 10 8 5 2
6 12
Time since immunomodulator initiation (months)
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Censored
Figure 2. Panel A: Cumulative probability of starting an immunomodulator from time of anti- tumour necrosis factor [TNF] monotherapy initiation in the overall 
population [n = 350]. Panel B: Cumulative probability of remaining on combination therapy from time of immunomodulator initiation in the 53 patients.
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on combination therapy [p  =  0.067]:  39.4%  [21.0%;  65.4%]  at 
12 months for patients with perianal disease and 56.2% [38.4%; 
79.6%] for patients with no perianal disease. The cumulative prob-
ability of experiencing an adverse event related to immumodulator 
use from time of drug initiation was 17.4% [8.6%;33.3%] and 22% 
[11.3%;40.4%] at 6 and 12 months, respectively [Supplementary 
Figure 2, available as Supplementary data at ECCO-JCC online]. 
This cumulative probability was 5.6% [0.8%;33.4%] at 12 months 
for patients on methotrexate and 32.8% [16.5%;58.4%] for 
patients on azathioprine [p  =  0.114]. At last follow-up, 13.5% 
[n  =  7] had uncontrolled disease, 13.5% [n  =  7] had partial 
response, and 73.1% [n = 38] were in clinical remission as judged 
by the physician [one patient with missing data at last follow-up]. In 
bivariate analysis, predictors of immunomodulator initiation were 
anti-TNF type [higher need for immunomodulator initiation for inf-
liximab than for adalimumab; p = 0.02] and first- vs second-/third-/
fourth-line anti-TNF therapy [p = 0.06] [Table 2]. In multivariate 
analysis, both variables were statistically significant [p = 0.0058 and 
0.014, respectively] [Table 2]. Predictors of clinical remission after 
immunomodulatory introduction are presented in Table 3. The type 
of immunomodulator was not a predictive factor of clinical remis-
sion after immunomodulator introduction [p  =  0.065, Table  3]. 
Two [10.5%] out of the 19 patients treated with methotrexate had 
uncontrolled disease (vs 15.1% [n = 5] of the 33 patients on aza-
thioprine); 5.3% [n = 1] had partial response (vs 18.2% [n = 6]); 
and 84.2% [n = 16] were in clinical remission (vs 66.7% [n = 22]) 
as judged by the physician.
Perianal disease was not a predictor of clinical remission at last 
follow-up after immunomodulator introduction [p = 0.065; table 3]: 
9.5% [n = 2] of the 21 patients with perianal disease and available data 
at last follow-up had uncontrolled luminal disease at last follow-up 
(vs 16.1% [n = 5] of the 31 patients with no perianal disease), 14.3% 
[n = 3] had partial response (vs 12.9% [n = 4] in the no perianal dis-
ease group), and 76.2% [n = 16] were in clinical remission (vs 71.0% 
[n = 22] in the no perianal disease group) as judged by the physician.
3.5. Resetting immunogenicity by adding 
azathioprine in case of loss of response
Pharmacokinetics of infliximab after adding azathioprine in IBD 
patients who lost response and having undetectable TRI with very 
high ATI [> 200 ng/ml] were analysed. A total of 13 CD patients 
[mean age: 36 years, sex ratio 1] with available data could be ana-
lysed. All 13 patients had permanent ATI defined by ATI > 200ng/
ml at two consecutive infliximab infusions. CDAI ranged between 
150 and 300 and faecal calprotectin level 450 to 800 µg/g stools. 
The mean TRI increased at 6 months from 0.015 [0.01–0.02] to 
0.9 [0.01–2.7] µg/ml [p = 0.01, Figure 3]. Conversely, mean ATI 
level decreased at 6 months from 320 [200–600] to 60 [10–500] 
[p = 0.01, Figure 4A]. For 7 out of 13 patients, the trough level 
Table 2. Bivariate and multivariate analyses on predictors of immunomodulator initiation.
Bivariate analysis Multivariate analysis
HR [95% CI] p-Value HR [95% CI] p-Value
Gender [male] 0.79 [0.46;1.37] 0.416
Active smoker 1.32 [0.72;2.42] 0.361
Localisation of disease *
 Ileum; L1 1 0.166
  Colon: L2 1.69 [0.80;3.56] 0.283
  Ileocolon: L3 1.43 [0.74;2.74] 
Behavioura,b
  Pure inflammatory: B1 1
  Stricturing: B2 0.46 [0.21;1.04] 0.063
  Penetrating: B3 0.81 [0.37;1.74] 0.585
Age at diagnosis [years]a
   < 16 1
 17–40 1.03 [0.46;2.32] 0.938
 > 40 1.24 [0.47;3.25] 0.665
Perianal disease 0.97 [0.56;1.67] 0.903
Previous intestinal resection 0.85 [0.47;1.53] 0.591
2nd/3rd/4th line of anti-TNF therapy vs 1st lineb 1.67 [0.97;2.87] 0.0622 2.00[1.15;3.49] 0.014
Anti-TNF type[IFX vs ADA] α 1.92 [1.10;3.35] 0.0214 2.23[1.26;3.95] 0.006
Concomitant treatment
 Oral 5-ASA 1.08 [0.62;1.86] 0.786
 Budesonide 1.41 [0.64;3.14] 0.396
 Systemic [oral or intravenous] 1.52 [0.68;3.36] 0303
 steroids 1.35 [0.73;2.49] 0.334
Indication of anti-TNF initiation
 Steroid-dependent disease 1.21 [0.62;2.34] 0.580
 Steroid-refractory disease 0.73 [0.31;1.71] 0.474
 Failure of a first anti-TNF therapy 1.12 [0.63;2.02] 0.694
 Flare 1.03 [0.44;2.42] 0.938
5-ASA, 5-aminosalicylic acid; IFX, infliximab; ADA, adalimumab; HR, hazard ratio. 95% CI, 95% confidence interval; TNF, tumour necrosis factor.
aAccording to the Montreal classification.
bFactors introduced in multivariate analysis.
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of infliximab was within normal range at 6 months following ini-
tiation of azathioprine [TRI > 1.5  µg/ml  with ATI  <  20 ng/ml] 
and all 7 patients were in clinical remission at 6 months [CDAI 
< 150] [Figure 4B]. A biomarker remission [faecal calprotectin < 
250 µg/g stools] was obtained at 4 months in 7 out of 13 patients 
[Supplementary Figure  3, available as Supplementary data at 
ECCO-JCC online] and all 7 patients also had trough level of 
infliximab within normal range. No factor at time of immu-
nomodulator initiation [disease duration, C-reactive protein level, 
duration of infliximab therapy, previous use of an immunomodu-
lator] was associated with clinical remission or pharmacokinet-
ics normalisation [considered as resetting of immunogenicity] 
[data not shown]. A TRI ≥ 1 µg/ml at 4 months predicted clinical 
remission, biomarker remission, and normalisation of both TRI 
and ATI at 6  months with positive predictive value and nega-
tive predictive value of 100%. Results were comparable to adali-
mumab therapy. Five patients presenting loss of response under 
adalimumab maintenance therapy [40 mg every other week] and 
with undetectable TRA and positive antibodies to adalimumab 
were optimised with the addition of azathioprine. Three out of 
five patients were in clinical remission at 6 months [CDAI < 150], 
with biomarker remission [faecal calprotectin < 250 µg/g stools] 
and trough level of adalimumab within therapeutic range [TRA 
> 4.9 µg/ml].
3.6. Crohn’s disease-related surgeries and 
hospitalisations
Among the 350 patients, the cumulative probability of having 
intestinal resection was 6.2% [4.0%; 9.4%] and 24.9% [19.2%; 
32.0%] at 1 and 5 years, respectively. Among the 350 patients, the 
cumulative probability of having at least one hospitalisation was 
7.4% [4.9%; 10.8%] and 19.2% [13.9%; 26.6%] at 1 and 5 years, 
respectively.
3.7. Safety in the overall population [n = 350]
A total of 157 out of 350 patients [44.8%] experienced adverse 
events judged as possibly related to anti-TNF therapy during fol-
low-up, with 30 serious adverse events [Table 4]. Of the 127 non-
serious adverse events, 43 were infections, 11 allergic reactions, 13 
psoriasiform lesions, 28 unspecific skin lesions, and 32 others; of 
the 30 serious adverse events, 7 were infections, 8 allergic reactions, 
4 psoriasiform lesions, 2 unspecific skin lesions, and 9 others. No 
cancer or lymphoma was detected during follow-up. The cumulative 
Table 3. Bivariate analysis on predictors of clinical remission after 
immunomodulator introduction.
Bivariate analysis
HR [95% CI] p-Value
Gender [male] 0.87 [0.45;1.68] 0.690
Active smoker 1.31 [0.62;2.77] 0.479
Disease locationa
  Ileum: L1 1
  Colon: L2 1.55 [0.61;3.95] 0.359
  Ileocolonic: L3 0.88 [0.39;1.96] 0.758
Behavioura,b
 Uncomplicated [B1] 1
 Complicated [B2 + B3] 1.21 [0.59;2.48] 0.593
Age at diagnosis [years]a
   < 16 1
 17–40 1.07 [0.43;2.63] 0.890
 > 40 1.25 [0.41;3.79] 0.689
Perianal disease 1.19 [0.61;2.34] 0.601
Previous intestinal resection 0.90 [0.45;1.80] 0.764
2nd/3rd/4th line of anti-TNF therapy vs 
1st line α
1.67 [0.83;3.30] 0.148
Anti-TNF type [IFX vs ADA] α 0.60 [0.29;1.26] 0.178
Concomitant treatment
 Oral 5-ASA 1.39 [0.61;3.22] 0.413
 Budesonide 1.18 [0.48;2.88] 0.714
 Systemic [oral or intravenous] 1.53 [0.76;30.7] 0.234
 Steroids 1.54 [0.79;2.97] 0.205
IMM type [methotrexate vs azathioprine] 1.94 [0.96;3.92] 0.065




5-ASA, 5-aminosalicylic acid; IFX, infliximab; ADA, adalimumab; IMM, 
immunomodulatory; TNF, tumour necrosis factor; HR, hazard ratio; CI, con-
fidence interval.
HR, hazard ratio. 95% CI, 95% confidence interval
aAccording to the Montreal classification.










M0 M2 M4 M6
Figure 3. Infliximab trough levels [µg/ml] before start of azathioprine treatment at Month [M] 0 (mean: 0.015 [0.01–0.02]) and at 6 months (M6; mean: 0.9 
[0.01–2.7]; p = 0.01) in 13 infliximab-treated patients.
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probability of experiencing at least one adverse event among the 350 
patients was 25.4% [21.0%; 30.7%] and 43.7% [37.7%; 50.6%] at 
1 and 5 years, respectively.
4. Discussion
This is the first study investigating the long-term efficacy and safety 
profile of anti-TNF monotherapy for CD. The SONIC trial clearly 
demonstrated that combination therapy is superior to anti-TNF 
monotherapy for maintaining steroid-free clinical remission at 
6 months.4 However, several studies showed that combination ther-
apy is associated with an increased risk of malignancies, particularly 
an increased risk of lymphoma.6,7 Importantly, this risk is known 
to be mainly driven by concomitant thiopurine use.6,7 By contrast, 
all available studies failed to identify an increased risk of malig-
nancy among IBD patients treated with anti-TNF monotherapy.6,7 
In this context, some physicians use anti-TNF as monotherapy in 
IBD patients, as demonstrated in a recent survey conducted among 
private gastroenterologists in France.5 Whether starting anti-TNF 
monotherapy should be considered as an option in clinical practice 
for CD patients is still a matter of debate.
We found that only 6% of patients were primary non-responders. 
























Iniximab trough levels > 1.5 with
antibodies to iniximab < 20 (n=7)
M2 M4 M6
Figure 4. Panel A: Antibodies to infliximab [ng/ml] before start of azathioprine treatment at Month [M] 0 (mean: 320 [200–600]) and at 6 months (M6; mean: 60 
[10–500]; p = 0.01) in 13 infliximab-treated patients. Panel B: Crohn’s Disease Activity Index [CDAI] scores before start of azathioprine treatment at Month [M] 0 
and at 6 months [M6] in 13 infliximab-treated patients.
Table 4. Safety [%, n] in the overall population [n = 350].
Adverse events 44.8% [157]
Serious adverse events 8.6% [30]
 -infections 23.3% [7]
 -allergic reactions 26.7% [8]
 -psoriasiform lesions 13.3% [4]
 -unspecific skin lesions 6.7% [2]
 -others 30.0% [9]
Non-serious adverse events 36.3% [127]
 -infections 33.9% [43]
 -allergic reactions 8.7% [11]
 -psoriasiform lesions 10.2% [13]
 -unspecific skin lesions 22.0% [28]
 -others 25.2% [32]
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the long-term clinical benefit of infliximab in 614 consecutive patients 
with CD from a single centre during a median follow-up of 55 months 
and showing that 10.9% of patients were primary non-responders to 
infliximab.10 Our data indicate that in the short term, monotherapy 
with anti-TNF therapy is highly efficacious in CD in a real-life setting.
However, long-term data are needed to further evaluate whether 
some patients can be treated with anti-TNF therapy without need-
ing a concomitant immunomodulator. We showed that only 15% of 
patients needed initiation of an immunomodulator during follow-up. 
Importantly, three-quarters of patients on anti-TNF monotherapy 
were in clinical remission as judged by the physician at last report, 
showing that most patients not needing an immunomodulator have 
long-term clinical benefit. In the overall population, the cumulative 
probability of having intestinal resection was 24.9% at 5 years and 
the cumulative probability of having at least one hospitalisation was 
19.2% at 5 years. In a recent French observational study of a refer-
ral-centre cohort, the cumulative probability of the first CD-related 
major abdominal surgery was 25.9% at 5 years.2 In CD, the annual 
incidence of hospitalisations was 20%.11 Loss of response is frequent 
with anti-TNF therapy in IBD.12,13 Consistently, we found that the 
cumulative probability of optimising anti-TNF therapy was 58.8% 
at 5 years. Overall, these findings indicate that starting with anti-TNF 
monotherapy does not seem to dramatically worsen disease outcomes.
Combination therapy reduces immunogenicity and increases 
anti-TNF trough levels.6,7 This likely contributes to the greater effi-
cacy profile of combination therapy over anti-TNF monotherapy. 
Starting a concomitant immunomodulator while being on anti-
TNF monotherapy is often perceived as a missed opportunity for 
these patients, as it might be too late to prevent immunogenicity. 
Preliminary findings suggest that this approach may be used for 
resetting immunogenicity in IBD patients on anti-TNF monotherapy 
losing drug response.8 However, this awaits confirmation in a larger 
series of patients. In our study, starting azathioprine treatment in 
case of loss of response to anti-TNF in 13 infliximab- and 5 adali-
mumab-treated patients induced clinical remission, biomarker remis-
sion, and normalisation of anti-TNF trough levels in 55% of patients 
at 6 months. It is noteworthy that one-quarter of patients starting 
an immunomodulator after initiation of anti-TNF monotherapy 
were still on combination therapy and three-quarters of these were 
in clinical remission at last follow-up. The safety profile of azathio-
prine, when introduced after start of anti-TNF monotherapy, is con-
sistent with previous reports on thiopurine in IBD. Overall, these 
results indicate that introduction of an immunomodulator could be 
considered in clinical practice among patients who lose response to 
anti-TNF monotherapy, as it may be efficacious in terms of clinical 
remission and improvement of pharmacokinetics profile.
Interestingly, independent predictors of immunomodulator ini-
tiation were anti-TNF type [higher need for immunomodulator 
initiation for infliximab than for adalimumab] and first- vs sec-
ond-/third-/fourth-line anti-TNF therapy in multivariate analysis. 
Recently, two meta-analyses showed that clinical remission rates at 
6 months or 1 year were similar with adalimumab monotherapy and 
with combination therapy in CD.14,15 However, all monoclonal anti-
bodies have the potential for immunogenicity. Furthermore, whereas 
combination therapy with infliximab is known to be more effective 
than infliximab monotherapy, no SONIC-like trial is available for 
adalimumab. The fact that first-line anti-TNF therapy was associ-
ated with a lower need for combination therapy may only reflect 
more refractory disease.
Limitations of our study include the retrospective study design 
and the lack of evaluation of objective signs of inflammation 
[C-reactive protein and endoscopy] due to missing data. We did not 
include a control group of patients receiving combination therapy 
as by definition this would lead to major bias due to uncontrolled 
study. However, there are several strengths. This is a large cohort 
of patients with CD [n = 350] treated over a 13-year period; large 
pharmacokinetics data after introduction of an immunomodulator 
were available in 18 patients; the mean duration of follow-up was 
42 months; and it was a multicentre cohort study. Our findings were 
confirmed by other groups.16,17
In conclusion, an immunomodulator was initiated in 15% of patients 
with Crohn’s disease starting anti-TNF monotherapy. Independent 
predictors of immunomodulator initiation were infliximab use and 
second-/third-/fourth-line anti-TNF therapy. Resetting immunogenic-
ity with an immunomodulator was effective in half of patients in a 
sub-study. Persistence of anti-TNF treatment at 5 years was observed 
in half of the 297 patients not starting an immumodulator during fol-
low-up. Taken together, our findings indicate that some CD patients 
could remain on anti-TNF monotherapy in the long term, without rep-
resenting a missed opportunity for these patients. This might improve 
the risk-benefit profile of current strategies based on a widespread and 
earlier use of biologicals in CD patients. Indeed, this may be a way to 
improve the long-term safety profile of anti-TNF agents by limiting 
the number of patients being exposed to combination therapy.
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